Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2008-03-31
2011-11-29
Aulakh, Charanjit (Department: 1625)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C546S070000, C546S048000, C514S283000
Reexamination Certificate
active
08067432
ABSTRACT:
A method for preparing a stable dispersion of a camptothecin, camptothecin prodrug, or analog thereof for administration to a patient in need thereof includes preparing a solution of the camptothecin, wherein the solution has a pH which places substantially an entirety of that camptothecin in a carboxylate form. The camptothecin may be a neutral camptothecin. The solution is next loaded into a liposome including at least one lipid, which may be a phospholipid. An intraliposomal pH is maintained which preserves substantially an entirety of the camptothecin in the carboxylate form. The liposomal dispersion is administered to an individual in need thereof, whereby the liposomes accumulate at and permeate into tumor tissue and an active, lactone form camptothecin is released in situ at the tumor site. Compositions formulated in accordance with the described method for treatment of a cancer in an animal in need thereof are provided also.
REFERENCES:
patent: 5552156 (1996-09-01), Burke
patent: 5736156 (1998-04-01), Burke
patent: 6352996 (2002-03-01), Cao et al.
patent: 6653319 (2003-11-01), Xiang et al.
patent: 6897200 (2005-05-01), Burke et al.
patent: 7060828 (2006-06-01), Madden et al.
patent: 7122553 (2006-10-01), Rahman et al.
patent: 2003/0215492 (2003-11-01), Ahmad et al.
patent: 2005/0019387 (2005-01-01), Rahman et al.
patent: 2005/0100590 (2005-05-01), Duena et al.
patent: 2005/0191344 (2005-09-01), Zalipsky et al.
patent: 1547580 (2005-06-01), None
patent: WO 2004/002454 (2004-01-01), None
Vijay Joguparthi et al., “Liposomal Delivery of Hydrophobic Weak Acids: Enhancement of Drug Retention Using a High Intraliposomal pH,” Journal of Pharmaceutical Sciences, vol. 97, No. 1, Jan. 2008, pp. 433-454.
J. Allen Zhang et al., “Development and characterization of a novel liposome-based formuation of SN-38,” International of Journal Pharmaceutics 270 (2004) 93-107.
Eric H. Kraut et al., “Final Results of a Phase I Study of Liposome Encapsulated SN-38 (LE-SN38): Safety, Pharmacogenomics, Pharmacokinetics, and Tumor Response,” ASCO 2005 Abstract 2017 (LE-SN38-101 Study), 4 pages.
Vigay Joguparthi et al., “Lipid Bilayer Permeability of the Lactone Form of a Lipophillic Camptothecin, DB-67,” 2006 AAPS Annual Meeting and Exposition, Oct. 31, 2006, 2 pages.
Vigay Joguparthi et al., “Controlled Release of Camptothecins by Intraliposomal pH Alteration: in Vitro Studies with DB-67,” 2006 AAPS Annual Meeting and Exposition, Oct. 28-Nov. 2, 2006, 1 pages.
Anderson Bradley D.
Joguparthi Vijay
Xiang Tian-Xiang
Aulakh Charanjit
King & Schlickli, PLLC
University of Kentucky Research Foundation
LandOfFree
Liposomal, ring-opened camptothecins with prolonged,... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Liposomal, ring-opened camptothecins with prolonged,..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Liposomal, ring-opened camptothecins with prolonged,... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4253209